Tags

Type your tag names separated by a space and hit enter

[STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS].
Harefuah 2015; 154(6):382-6, 404H

Abstract

Statins (HMG-CoA reductase inhibitors) are first-line agents for the management of hyperlipidemia in patients at high risk of cardiovascular events and their use for cardiovascular disease prevention is clearly supported by clinical evidence. Although safe and generally well tolerated, there is growing evidence to suggest that statins are associated with an elevated occurrence of new-onset diabetes mellitus. The incidence of this adverse effect is not negligible, especially for specific subsets of patients. Statins remain the cornerstone for primary and secondary cardiovascular prevention, but specific attention to glucose metabolism and metabolic syndrome features should be given before and during statin treatment, especially in cohorts at greater risk, and a potential tailored statin treatment based on the patient's cardiovascular and metabolic risk profile might emerge as the safest therapeutic approach. The main purpose of this review is to discuss the clinical evidence regarding the association of statin use with new onset diabetes mellitus, the cardiovascular benefit/risk ratio with statins, and the rationale for individualized statin therapy. Future trials with adequate and long follow-up designed to assess the benefit/risk ratio of a specific statin will further refine the basis of this strategy.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

heb

PubMed ID

26281083

Citation

Lavie, Gil, and Shai Cohen. "[STATINS for the PREVENTION of CARDIOVASCULAR DISEASE and DIABETES INCIDENCE--THE BENEFITS VERSUS the RISKS]." Harefuah, vol. 154, no. 6, 2015, pp. 382-6, 404.
Lavie G, Cohen S. [STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS]. Harefuah. 2015;154(6):382-6, 404.
Lavie, G., & Cohen, S. (2015). [STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS]. Harefuah, 154(6), pp. 382-6, 404.
Lavie G, Cohen S. [STATINS for the PREVENTION of CARDIOVASCULAR DISEASE and DIABETES INCIDENCE--THE BENEFITS VERSUS the RISKS]. Harefuah. 2015;154(6):382-6, 404. PubMed PMID: 26281083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS]. AU - Lavie,Gil, AU - Cohen,Shai, PY - 2015/8/19/entrez PY - 2015/8/19/pubmed PY - 2015/9/9/medline SP - 382-6, 404 JF - Harefuah JO - Harefuah VL - 154 IS - 6 N2 - Statins (HMG-CoA reductase inhibitors) are first-line agents for the management of hyperlipidemia in patients at high risk of cardiovascular events and their use for cardiovascular disease prevention is clearly supported by clinical evidence. Although safe and generally well tolerated, there is growing evidence to suggest that statins are associated with an elevated occurrence of new-onset diabetes mellitus. The incidence of this adverse effect is not negligible, especially for specific subsets of patients. Statins remain the cornerstone for primary and secondary cardiovascular prevention, but specific attention to glucose metabolism and metabolic syndrome features should be given before and during statin treatment, especially in cohorts at greater risk, and a potential tailored statin treatment based on the patient's cardiovascular and metabolic risk profile might emerge as the safest therapeutic approach. The main purpose of this review is to discuss the clinical evidence regarding the association of statin use with new onset diabetes mellitus, the cardiovascular benefit/risk ratio with statins, and the rationale for individualized statin therapy. Future trials with adequate and long follow-up designed to assess the benefit/risk ratio of a specific statin will further refine the basis of this strategy. SN - 0017-7768 UR - https://www.unboundmedicine.com/medline/citation/26281083/[STATINS_FOR_THE_PREVENTION_OF_CARDIOVASCULAR_DISEASE_AND_DIABETES_INCIDENCE__THE_BENEFITS_VERSUS_THE_RISKS]_ L2 - http://www.diseaseinfosearch.org/result/2236 DB - PRIME DP - Unbound Medicine ER -